Grupp S, Maude S, Baruchel A, et al. Tisagenlecleucel appears effective and safe in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia with high-risk cytogenetic abnormalities. 24th Congress of EHA, abstract S1618.
‘Risicomodel IPSS-M dient standaard te worden gebruikt bij MDS’
okt 2023 | MDS, Stamceltransplantatie